Videos

The 34th Annual Miami Breast Cancer Conference® featured a recap of significant research from the 2016 ASCO Annual Meeting and the 2016 San Antonio Breast Cancer Symposium.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 24, 2017, to discuss a new drug application for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, according to a statement from the developer of the TKI, Puma Biotechnology.

Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.

Research on a scalp-cooling device to help patients with breast cancer avoid hair loss during chemotherapy illustrates this question: what level of evidence might individual clinicians require before they would suggest, recommend, or support the use of a particular approach in treating patients outside the realm of the mandates of governmental agencies or payers?

Steven J. Katz, MD, discusses his study of patient reaction to surgeon recommendations about contralateral prophylactic mastectomy for patients with breast cancer.

Mary L. (Nora) Disis, MD, professor of Medicine, Department of Medicine, University of Washington School of Medicine, discusses immunotherapy for patients with breast cancer.

Fatima Cardoso, MD, coordinator, European School of Oncology Breast Cancer Program, Secretary General, European Organization for Research and Treatment of Cancer, director, Breast Unit, Campalimaud Clinical Cancer Center, discusses the rationale behind the Global mBC Vision 2025 Call-to-Action.

According to results from the PAMELA trial, women with the HER2-enriched subtype of early-stage, HER2-positive breast cancer were more likely to have a pathological complete response when treated with dual HER2-blockade.

Experts discuss the most effective ways to use new targeted therapies for patients with advanced hormone receptor-positive breast cancer in an OncLive Peer Exchange® panel.

Investigators are seeking to determine whether adding tucatinib (ONT-380), a novel small-molecule HER2 inhibitor, to standard therapies will improve outcomes for patients with progressive metastatic HER2-positive breast cancer, including those with brain tumors.

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses selection criteria for adjuvant systemic therapy for patients with breast cancer.

According to results presented at the 2017 AACR Annual Meeting, 10% of patients showed impressive long-term survival in a phase I study of single agent anti-PD-L1 atezolizumab (Tecentriq) in patients with metastatic triple-negative breast cancer.

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.

The FDA has granted a full approval to palbociclib (Ibrance) for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

Sara A. Hurvitz, MD, discussed the use of anthracycline regimens in breast cancer during a talk at the 2017 Miami Breast Cancer Conference.

Mark D. Pegram, MD, discusses resistance mechanisms being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer.

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab and zoledronic acid in patients with breast cancer.